SCHEMBL7116149

SCHEMBL7116149

CCOC(=O)c1cc(Oc2ccccc2N)cc(C(=O)O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.48
ALDH1A1 P00352 4/20 0.48
HSD17B10 Q99714 2/20 0.48
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
F2 P00734 1/20 0.46
F10 P00742 1/20 0.46
GAA P10253 2/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAOA P21397 1/20 0.43
TSHR P16473 2/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6341195 0.86 GAA (0.50) USP2ALDH1A1CYP2C9CYP2C19GAA
SCHEMBL7117318 0.81 ALDH1A1 (0.48) ALDH1A1GAALMNAMEN1KMT2A
SCHEMBL7116144 0.79 USP2 (0.73) USP2ALDH1A1HSD17B10GAATSHR
SCHEMBL7119443 0.79 ALDH1A1 (0.50) ALDH1A1HSD17B10GAALMNACYP1A2
SCHEMBL7118376 0.79 ALDH1A1 (0.54) ALDH1A1HSD17B10GAATSHRMEN1
SCHEMBL6840897 0.78 PTGS2 (0.55) ALDH1A1CYP2C9CYP2C19F2F10
SCHEMBL14879708 0.77 USP2 (0.55) USP2ALDH1A1HSD17B10CYP2C9CYP2C19
SCHEMBL7234951 0.77 CYP2C19 (0.70) CYP2C9CYP2C19LMNACYP1A2CYP3A4
SCHEMBL3327442 0.77 CYP2C19 (0.70) CYP2C9CYP2C19LMNACYP1A2CYP3A4
SCHEMBL330220 0.76 NPC1 (0.60) ALDH1A1HSD17B10CYP2C9CYP2C19GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics KRISTIANSEN MARIT (DK) 2003-10-02 US disclosed
US-6590118-B1 Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) NOVO NORDISK A/S (DK) 2003-07-08 US disclosed
EP-1220832-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2002-07-10 EP disclosed
WO-2001023347-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics PYGL, GYS2, PYGM USP2 2333/4885ALDH1A1 901/4885HSD17B10 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.